Clinical Trial Update: Comparison of Outcomes Between Low Dose Emicizumab and Factor VIII in Clinically Severe Hemophilia A [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update comparing low-dose emicizumab to Factor VIII in patients with clinically severe hemophilia A without inhibitor, focusing on joint bleeds…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Emicizumab (emicizumab)
• Factor VIII (Factor VIII)

Snippet

Sponsor: Chulalongkorn University | Conditions: Severe Hemophilia A Without Inhibitor, Joint Bleed | Phase 2, Phase 3 | Status: UNKNOWN